Predicting dupilumab treatment outcome in patients with primary diffuse type 2 chronic rhinosinusitis-Reference-Cited by-同舟云学术

Predicting dupilumab treatment outcome in patients with primary diffuse type 2 chronic rhinosinusitis

Published:2022-10-10 Issue:4 Volume:78 Page:1036-1046
ISSN:0105-4538
Container-title:Allergy
language:en
Short-container-title:Allergy

Author:

Soyka Michael B.¹,Ryser Fabio S.²,Brühlmann Catrin¹,Fehr Danielle³⁴⁵^ORCID,Dülgeroglu Jacqueline²,Schmid‐Grendelmeier Peter³⁵^ORCID,Brüggen Marie‐Charlotte³⁴⁵^ORCID,Steiner Urs C.²

Affiliation:

1. Department of Otorhinolaryngology, Head and Neck Surgery University Hospital Zurich, University of Zurich Zurich Switzerland

2. Department of Immunology University Hospital Zurich, University of Zurich Zurich Switzerland

3. Allergy Unit, Department of Dermatology University Hospital Zurich, University of Zurich Zurich Switzerland

4. Faculty of Medicine University of Zurich Zurich Switzerland

5. Christine Kühne‐Center for Allergy Research and Education Davos Switzerland

Funder

Kurt und Senta Herrmann Stiftung

LEO Pharma Research Foundation

Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung

Universität Zürich

Publisher

Wiley

Subject

Immunology,Immunology and Allergy

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/all.15532

Reference40 articles.

1. Inflammatory endotypes of chronic rhinosinusitis based on cluster analysis of biomarkers

2. Real‐life assessment of chronic rhinosinusitis patients using mobile technology: The mySinusitisCoach project by EUFOREA

3. Efficacy and safety of treatment with biologicals for severe chronic rhinosinusitis with nasal polyps: A systematic review for the EAACI guidelines

4. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials

5. Real‐life observational cohort verifies high efficacy of dupilumab for chronic rhinosinusitis with nasal polyps

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Screening olfaction under dupilumab in chronic rhinosinusitis with nasal polyps;Rhinology Journal;2024-07-01

2. Entscheidungsfindung bei der Behandlung der chronischen Rhinosinusitis mit Nasenpolypen in der Ära der Biologika;HNO;2024-02-20

3. EUFOREA/EPOS2020 statement on the clinical considerations for CRSwNP care;Allergy;2023-12-18

4. Type 2 Biomarkers for the Indication and Response to Biologics in CRSwNP;Current Allergy and Asthma Reports;2023-11-21

5. Precision medicine in chronic rhinosinusitis – using endotype and endotype-driven therapeutic options;Expert Review of Clinical Immunology;2023-07-04